Format

Send to

Choose Destination
Science. 2014 Mar 7;343(6175):1151-4. doi: 10.1126/science.1248707. Epub 2014 Mar 4.

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Author information

1
Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA.

Abstract

GSK1265744 (GSK744) is an integrase strand-transfer inhibitor that has been formulated as a long-acting (LA) injectable suitable for monthly to quarterly clinical administration. GSK744 LA was administered at two time points 4 weeks apart beginning 1 week before virus administration, and macaques were challenged weekly for 8 weeks. GSK744 LA, at plasma concentrations achievable with quarterly injections in humans, protected all animals against repeated low-dose challenges. In a second experiment, macaques were given GSK744 LA 1 week before virus administration and challenged repeatedly until infection occurred. Protection decreased over time and correlated with the plasma drug levels. With a quarterly dosing schedule in humans, our results suggest that GSK744 LA could potentially decrease adherence problems associated with daily preexposure prophylaxis (PrEP).

PMID:
24594934
PMCID:
PMC4308974
DOI:
10.1126/science.1248707
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center